{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:03:58Z","timestamp":1770822238164,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,10,20]],"date-time":"2005-10-20T00:00:00Z","timestamp":1129766400000},"content-version":"vor","delay-in-days":4310,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Laboratory Analysis"],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The absolute tissue specificity of prostate specific antigen (PSA) allows the use of PSA test not only for detecting recurrence or metastasis at an early stage after radical prostatectomy but also for screening prostate cancer if combined with digital rectal examination. There is also a need to improve the current PSA test to better differentiate between prostate cancer and benign prostate hyperplasia (BPH). Because of these clinical applications, a much greater demand was placed on PSA test for extra sensitivity, accuracy, and precision even within the normal PSA concentration range. However, the current commercial assay kits for PSA do not provide correct PSA values. Many factors contributing to the problem include the specificity of the anti\u2010PSA antibodies, the composition of the calibrator, the PSA values assigned to the calibrator, the PSA isoform used for anti\u2010PSA antibody preparation, the test design, and the composition of the diluent. Most problems were derived from the failure of realizing earlier that the majority of the PSA exists in serum not as free PSA but as complexes with protease inhibitors. Other problems, such as constantly changing composition of various forms of PSA in serum specimens, and different clearance rates for various forms of PSA make almost impossible to develop an ideal assay for PSA. Therefore, we suggest that test should be designed for measuring PSA\u2010ACT (PSA\u2010\u03b11\u2010antichymotrypsin) complex only. Changing the focus from the measurement of total PSA of various forms to the PSA\u2010ACT complex alone may improve the differentiation between prostate cancer and BPH but may also simplify the selection of anti\u2010PSA antibodies and the preparation of calibrator for the assay. \u00a9 1994 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jcla.1860080110","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:01:36Z","timestamp":1173132096000},"page":"51-62","source":"Crossref","is-referenced-by-count":56,"title":["Assay for prostate specific antigen (PSA): Problems and possible solutions"],"prefix":"10.1002","volume":"8","author":[{"given":"James T.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,10,20]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"1051","article-title":"Specific antigen similarity between malignant adult and normal fetal tissues of the human digestive system","volume":"44","author":"Gold P","year":"1965","journal-title":"J Clin Invest"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1972.45"},{"key":"e_1_2_1_4_2","first-page":"25","article-title":"Tumour Markers","volume":"3","author":"Bagshawe KD","year":"1977","journal-title":"Essays Med Biochem"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-419X(76)90007-X"},{"key":"e_1_2_1_6_2","first-page":"1","article-title":"Carcinoembryonic antigen (CEA) in the diagnosis and management of colorectal cancer","volume":"26","author":"Wu JT","year":"1986","journal-title":"ASCP Check Sample"},{"key":"e_1_2_1_7_2","first-page":"1","article-title":"Monoclonal immunoassays of tumor markers","volume":"28","author":"Wu JT","year":"1988","journal-title":"ASCP Check Sample"},{"key":"e_1_2_1_8_2","first-page":"17","article-title":"Expression of monoclonal antibody\u2010defined tumor markers in four carcinomas","volume":"19","author":"Wu JT","year":"1989","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_1_9_2","first-page":"159","article-title":"Purification of a human prostate\u2010specific antigen","volume":"17","author":"Wang MC","year":"1979","journal-title":"Invest Urol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/clinchem\/39.2.181","article-title":"Prostate\u2010specific antigen: Biochemistry, analytical methods, and clinical application","volume":"39","author":"Armbruster D","year":"1993","journal-title":"Clin Chem"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38491-4"},{"key":"e_1_2_1_12_2","first-page":"179","volume-title":"Cancer Research XIX","author":"Wang MC","year":"1982"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.10.3166"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42630-9"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)41037-8"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104253241702"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0022-5347(17)38746-3","article-title":"Identification of residual cancer in the prostate following radiation therapy: Role of transrectal ultrasound guided biopsy and prostate\u2010specific antigen","volume":"142","author":"Kabalin JN","year":"1989","journal-title":"J Urol"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37393-7"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37394-9"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.1992.03480160073037","article-title":"Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease","volume":"267","author":"Carter HB","year":"1992","journal-title":"JAMA."},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/clinchem\/33.10.1916","article-title":"Prostatespecific antigen as a marker for prostate cancer: A monoclonal and a polyclonal immunoassay compared","volume":"33","author":"Chan DW","year":"1987","journal-title":"Clin Chem"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42627-9"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1093\/clinchem\/29.12.2049","article-title":"Interference with CEA radioimmunoassays by glycosaminoglycans and their removal","volume":"29","author":"Wu JT","year":"1983","journal-title":"Clin Chem"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39789-6"},{"key":"e_1_2_1_25_2","volume-title":"Clinical Aspects of Prostate Cancer","author":"Myrtle JF","year":"1989"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/clinchem\/38.10.2044","article-title":"Evaluation of the Abbott IMx\u00ae automated immunoassay of prostate\u2010specific antigen","volume":"38","author":"Vessella RL","year":"1992","journal-title":"Clin Chem"},{"key":"e_1_2_1_27_2","first-page":"41","article-title":"Multisite clinical evaluation of an automated chemiluminescent immunoassay for prostate specific antigen (ACS\u2122 PSA)","volume":"7","author":"Bluestein B","year":"1992","journal-title":"J Tumor Mark Oncol"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(84)90256-0"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1990.tb19466.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112185"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6369538"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920701)70:1 <230::AID-CNCR2820701310>3.0.CO;2-Y"},{"key":"e_1_2_1_33_2","first-page":"222","article-title":"A complex between prostate\u2010specific antigen in serum and \u03b11\u2010 Antichymotrypsin is the major form of prostate\u2010specific antigen in serum of patients with prostatic cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer","volume":"51","author":"Stenman UH","year":"1991","journal-title":"Can Res"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35408-3"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/clinchem\/37.9.1618","article-title":"Prostate\u2010specific antigen in serum occurs predominantly in complex with \u03b11\u2010Antichymotrypsin","volume":"37","author":"Lilja H","year":"1991","journal-title":"Clin Chem"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000226754"},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/clinchem\/37.6.1133","article-title":"Variants of prostate\u2010specific antigen separated by concanavalin A","volume":"37","author":"Chan DW","year":"1991","journal-title":"Clin Chem"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39788-4"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39790-2"},{"key":"e_1_2_1_40_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/clinchem\/36.1.92","article-title":"Time\u2010resolved immunofluorometric assay of human prostate specifically antigen","volume":"36","author":"Vihko P","year":"1990","journal-title":"Clin Chem"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)40630-6"},{"key":"e_1_2_1_42_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-5347(17)36497-2","article-title":"False positive prostate specific antigen values in the sera of women with renal cell carcinoma","volume":"148","author":"Pummer K","year":"1992","journal-title":"J Urol"},{"key":"e_1_2_1_43_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/clinchem\/36.1.53","article-title":"Determination of prostate\u2010specific antigen in serum by immunoradiometric assay","volume":"36","author":"Lindstedt G","year":"1990","journal-title":"Clin Chem"},{"key":"e_1_2_1_44_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/clinchem\/37.1.113","article-title":"Storage conditions for serum for estimating prostate\u2010specific antigen","volume":"37","author":"Simm B","year":"1991","journal-title":"Clin Chem"},{"key":"e_1_2_1_45_2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/clinchem\/38.5.735","article-title":"Ultrasensitive radioimmunoassay of prostate\u2010specific antigen","volume":"38","author":"Graves HB","year":"1992","journal-title":"Clin Chem"}],"container-title":["Journal of Clinical Laboratory Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcla.1860080110","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.1860080110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T17:38:13Z","timestamp":1698169093000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcla.1860080110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1002\/jcla.1860080110"],"URL":"https:\/\/doi.org\/10.1002\/jcla.1860080110","archive":["Portico"],"relation":{},"ISSN":["0887-8013","1098-2825"],"issn-type":[{"value":"0887-8013","type":"print"},{"value":"1098-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}